| HOME >> BIOLOGY >> TECHNOLOGY |
Remodulin and Tyvaso are registered trademarks of United Therapeutics Corporation.
Adcirca is a registered trademark of Eli Lilly and Company.
UNITED THERAPEUTICS CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share data)Three Months Ended December 31,Year Ended December 31,2010200920102009Revenues:Net product sales
$
163,445$
105,945$
591,881$
357,870Service sales
2,7382,69710,75310,751License fees
2942811,1971,227Total revenues
166,477108,923603,831369,848Operating expenses:Research and development
62,25541,032166,761122,188Selling, general and administrative
74,99856,577199,600176,338Cost of product sales
18,53612,23367,71640,890Cost of service sales
1,6371,2635,7494,431Total operating expenses
157,426111,105439,826343,847(Loss) income from operations
9,051(2,182)164,00526,001Other income (expense):Interest income
6291,0052,9395,146Interest expense
(5,459)(3,659)(19,714)(12,875)Equity loss in affiliate
(30)(42)(160)(141)Other, net
314145769636Total other (expense) income, net
(4,546)(2,551)(16,166)(7,234) Income (loss) before income tax
4,505(4,733)147,83918,767Income tax benefit (expense)
5,0391,403(41,923)695Net income (loss)
$
9,544$
(3,330)$
105,916$
19,462Net income (loss) per common share:Basic
$
0.17$
(0.06)$
1.89$
0.37Diluted
$
0.15$
(0.06)$
1.78$
0.35Weighted average number of common shares outstanding:Basic
57,18753,92656,14253,314Diluted
61,71553,92659,51656,133SELECTED CONSOLIDATED BALANCE SHEET DATA(In thousands)December 31,20102009Cash, cash equivalents and marketable securities (excluding restricted amounts of $5,122 and $39,976, respectively)
$
759,932$
378,120Tota
'/>"/>
| SOURCE United Therapeutics Corporation Copyright©2010 PR Newswire. All rights reserved |